Trial Profile

A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 04 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 8853 (Primary) ; Crefmirlimab
Indications Carcinoma; Colorectal cancer; Non-small cell lung cancer; Urogenital cancer
Focus Adverse reactions; First in man
Sponsors AstraZeneca

10 Apr 2024 Results (n=16, data cut-off 6 June 2023) assessing safety of AZD8853, presented at the 115th Annual Meeting of the American Association for Cancer Research
11 Jul 2023 Status changed from recruiting to discontinued. This study was terminated in accordance to protocol Section 4.4, based on the overallrisk-benefit profile observed to date.
05 Jul 2022 Planned End Date changed from 1 Jul 2024 to 20 Jun 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com